ArticleCureus2025
Effectiveness of the Traditional Japanese Herbal Medicine, Yokuinin (Kampo), in the Treatment of Cervical Precancerous Lesions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Kampo Medicines Modulate Angiogenic, Antioxidant, and Inflammatory Pathways in Human Preclinical Models: Implications for Preeclampsia.Antioxidants (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Human papillomavirus (HPV) infection precedes cervical dysplasia, culminating in cervical cancer. Yokuinin extract, used for treating verruca vulgaris caused by HPV, exhibits potential antitumor activity against cervical cancer and mild cervical dysplasia. We examined the usefulness of Yokuinin in the treatment of cervical precancerous lesions. Methods This retrospective study included 73 female patients with verrucous skin lesions and mildly abnormal cervical cytology diagnosed between April 2019 and August 2021. Of the 73 patients, 34 received Yokuinin treatment whereas 39 did not. The Yokuinin-treated patients received 1.0 g Yokuinin orally divided into three doses daily. Evaluation criteria included retested cervical cytology, time to negative cervical cytology (negative for intraepithelial lesions or malignancies), and side effects. Statistical analyses employed the Mann-Whitney U test and chi-square test, indicating a statistically significant difference (p<0.05). Results Yokuinin-treated patients were significantly more likely to achieve normal cytology (NILM) status (p= 0.0441). Median time to NILM was three months for Yokuinin-treated versus five months for non-Yokuinin-treated group, indicating that the Yokuinin-treated group achieved NILM significantly earlier (p= 0.0011). Additionally, high-risk HPV-positive patients were more likely to develop NILM in a short period after Yokuinin administration, and premenopausal patients also developed NILM in a short period. No adverse effects were associated with Yokuinin administration. Conclusion Yokuinin administration effectively normalized precancerous cervical lesions, with expedited normalization observed in HPV-positive and premenopausal cases. Yokuinin emerges as a promising treatment for cervical precancerous lesions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.